SG Americas Securities LLC Acquires 36,938 Shares of Amicus Therapeutics, Inc. $FOLD

SG Americas Securities LLC boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 53.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 106,358 shares of the biopharmaceutical company’s stock after buying an additional 36,938 shares during the period. SG Americas Securities LLC’s holdings in Amicus Therapeutics were worth $1,515,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Ion Asset Management Ltd. acquired a new position in Amicus Therapeutics in the 3rd quarter valued at approximately $6,875,000. Norges Bank bought a new position in shares of Amicus Therapeutics during the second quarter valued at $18,540,000. Jump Financial LLC boosted its position in Amicus Therapeutics by 246.3% in the second quarter. Jump Financial LLC now owns 1,406,563 shares of the biopharmaceutical company’s stock valued at $8,060,000 after buying an additional 1,000,395 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new position in shares of Amicus Therapeutics in the 3rd quarter worth approximately $2,961,000. Finally, Nordea Investment Management AB acquired a new position in Amicus Therapeutics in the third quarter worth $7,843,000.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 22,500 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $14.35, for a total transaction of $322,875.00. Following the completion of the sale, the chief executive officer directly owned 998,680 shares in the company, valued at $14,331,058. This trade represents a 2.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.20% of the stock is owned by company insiders.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $14.45 on Tuesday. The firm has a 50-day moving average of $14.35 and a 200-day moving average of $11.93. The company has a market cap of $4.54 billion, a PE ratio of -180.63 and a beta of 0.48. The company has a debt-to-equity ratio of 1.43, a current ratio of 2.84 and a quick ratio of 1.88. Amicus Therapeutics, Inc. has a one year low of $5.51 and a one year high of $14.46.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.03). Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. The business had revenue of $185.21 million during the quarter, compared to analyst estimates of $185.00 million. During the same period in the previous year, the business earned $0.09 earnings per share. The business’s quarterly revenue was up 23.7% on a year-over-year basis. As a group, equities analysts forecast that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on FOLD shares. Guggenheim cut shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 5th. Citigroup reaffirmed a “neutral” rating and issued a $14.50 price target (down from $17.00) on shares of Amicus Therapeutics in a research note on Monday, December 22nd. TD Cowen lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 price target for the company. in a report on Monday, December 22nd. Leerink Partners cut Amicus Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $17.00 to $14.50 in a research note on Monday, December 29th. Finally, Zacks Research cut Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 26th. Three analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Amicus Therapeutics currently has an average rating of “Hold” and an average target price of $15.39.

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.